BioStock Investor Meeting: Interview with Cyxone

Cyxone’s interim CEO Carl-Magnus Högerkorp was interviewed by BioStock after his presentation at the BioStock Investor Meeting. In the interview, Högerkorp tells us more about the upcoming phase II study with the company’s leading candidate Rabeximod, and answers the question of where the company expects to be in a year.

See the full interview at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-interview-with-cyxone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se